Cilostazol and Abrocitinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Cilostazol
Abrocitinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Cilostazol (Pletal) and abrocitinib (Cibinqo) can raise your risk of bleeding when taken together. Cilostazol is an antiplatelet medicine, meaning it makes your platelets less sticky so they don't clot as easily. Abrocitinib, a medicine for eczema, can also lower your platelets, especially early in treatment. Put together, these effects can add up and make bleeding or bruising more likely.
Because of this, the two are generally not recommended together, especially in the first 3 months of abrocitinib. Please don't stop either medicine on your own. Talk with your pharmacist or doctor so they can pick the safest plan for you.
Effect: Additive risk of bleeding via combined effects on hemostasis. Cilostazol is an antiplatelet agent (phosphodiesterase III inhibitor); abrocitinib is associated with dose-dependent thrombocytopenia, most pronounced during early therapy.
- Direction: Additive PD interaction (no prodrug consideration); increased bleeding risk.
- Severity: Contraindicated per labeling during the first 3 months of abrocitinib treatment (antiplatelet agents other than low-dose aspirin, 81 mg/day or less).
- Evidence: Theoretical/labeling-based; onset unspecified.
- Management: Avoid concurrent use in the initial 3-month period; consult prescriber regarding alternative antiplatelet strategy and platelet monitoring.
What happens
Increased risk of bleeding
Interaction Deep Dive
Giving abrocitinib together with antiplatelet drugs is contraindicated throughout the initial 3 months of therapy, with the exception of low-dose aspirin (no more than 81 mg per day), because of a heightened bleeding risk1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
This combination is generally avoided, especially during the first 3 months of abrocitinib. Only low-dose aspirin (81 mg daily or less) is considered acceptable with abrocitinib in that early window; cilostazol is not.
- Keep taking both medicines exactly as prescribed until you speak with your care team, and do not stop either one on your own.
- Tell your pharmacist or prescriber that you take both so they can decide on the safest approach, which may include choosing an alternative or delaying one medicine.
- Watch for and promptly report unusual bruising, nosebleeds, blood in urine or stool, or bleeding that won't stop.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Cilostazol and Abrocitinib together?
Cilostazol and abrocitinib together can add up to raise your bleeding risk, and this pairing is generally avoided during the first 3 months of abrocitinib. Talk to your pharmacist or doctor before changing anything. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Cilostazol and Abrocitinib interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Cilostazol and Abrocitinib interaction managed?
This combination is generally avoided, especially during the first 3 months of abrocitinib. Only low-dose aspirin (81 mg daily or less) is considered acceptable with abrocitinib in that early window; cilostazol is not. Keep taking both medicines exactly as prescribed until you speak with your care team, and do not stop either one on your own. Tell your pharmacist or prescriber that you take both s… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Cilostazol or Abrocitinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CIBINQO(TM) oral tablets, abrocitinib oral tablets. Pfizer Labs (per FDA), New York, NY, 2022. DailyMed
Keep reading about Cilostazol
Keep reading about Abrocitinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist